ucsf logo

Priya Dhawan, MD

She | Her | HersNeuromuscular Medicine • Neurology
Neuromuscular Parnassus
415-353-2273
ucsf logo

Priya Dhawan, MD

She | Her | HersNeuromuscular Medicine • Neurology
Neuromuscular Parnassus
415-353-2273

On this page

About me

Dr. Priya Dhawan is a neuromuscular neurologist who cares for patients with peripheral nerve, muscle and neuromuscular junction disorders.

Dhawan has expertise in treating neurological complications from systemic diseases and blood disorders, as well as amyloidosis (a condition in which abnormal proteins accumulate in tissue); evaluating patients with peripheral nerve injuries; and diagnosing hereditary muscle disorders. She has a strong interest in educating trainees in electrophysiological diagnosis and treatment of neuromuscular disorders.

Working with the University of Rwanda as part of an additional partnership with the University of British Columbia, Dhawan is active in global health efforts spanning medical education, patient care and research.

Dhawan earned her medical degree from Saba University School of Medicine. She completed a residency in adult neurology and a fellowship in neuromuscular medicine at the Mayo Clinic.

Education & training

Board certification

  • Electrodiagnostic Medicine, American Board of Electrodiagnostic Medicine

Fellowship

  • Neuromuscular Medicine, Mayo Clinic - GME

Residency

  • Neurology, Mayo Clinic Hospital GME (Phoenix, AZ)

Internship

  • Transitional, Mayo Clinic Hospital GME (Phoenix, AZ)

Degree

  • MD, Saba University School of Medicine

My expertise

Locations

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

    For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.